Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.45 |
| ▸ | SRC | P12931 | 5/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30226495 | 1.00 | ABL1 (0.45) | ABL1SRCNUDT1SYKCYP1A2 | |
| SCHEMBL17126117 | 0.86 | NUDT1 (0.48) | NUDT1ALPLALDH1A1MAPT | |
| SCHEMBL31420506 | 0.86 | NUDT1 (0.41) | NUDT1DAOAXLPRKCI | |
| SCHEMBL26620152 | 0.83 | ABL1 (0.43) | ABL1SRCNUDT1SYKCYP1A2 | |
| SCHEMBL30883103 | 0.83 | ABL1 (0.43) | ABL1SRCNUDT1SYKCYP1A2 | |
| SCHEMBL23147720 | 0.83 | NUDT1 (0.46) | ABL1NUDT1SYKDAOAXL | |
| SCHEMBL20839678 | 0.83 | GRIN1 (0.46) | NUDT1DAOAXLPRKCI | |
| SCHEMBL30239581 | 0.83 | GRIN1 (0.46) | NUDT1DAOAXLPRKCI | |
| SCHEMBL22554309 | 0.82 | ABL1 (0.44) | ABL1SRCNUDT1CYP1A2DAO | |
| SCHEMBL20839976 | 0.82 | NUDT1 (0.63) | NUDT1SYKDAOMAPTAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312938-A1 | Pyrrolopyridine Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| US-20250011299-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-01-09 | — | — | US | disclosed |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4182308-B1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-09-04 | — | — | EP | disclosed |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| EP-4373816-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4182323-B1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-04-24 | — | — | EP | disclosed |
| US-20150376185-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-9145416-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9102673-B2 | Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150011470-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8859577-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140155413-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. | 2014-06-05 | — | — | US | disclosed |
| EP-2621493-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130190334-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012042433-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20110312938-A1 | Pyrrolopyridine Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190334-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, PC | ABL1 4620/4885SRC 4173/4885NUDT1 2815/4885 |
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | ABL1 445/4885SRC 197/4885NUDT1 3400/4885 |
| US-20150376185-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, PC | ABL1 4501/4885SRC 4015/4885NUDT1 2792/4885 |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | USP7, USP47, USP2 | ABL1 2350/4885SRC 3574/4885NUDT1 3636/4885 |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | ALK, TGFBR1, ACVR1 | ABL1 173/4885SRC 1524/4885NUDT1 2231/4885 |
| US-20140155413-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGF, NGFR, NTRK2 | ABL1 79/4885SRC 167/4885NUDT1 3239/4885 |
| US-20250011299-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | ABL1 173/4885SRC 1524/4885NUDT1 2231/4885 |
| US-20150011470-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, PC | ABL1 4501/4885SRC 4015/4885NUDT1 2792/4885 |
| US-20110312938-A1 | Pyrrolopyridine Carboxylic Acid Derivatives | SDHA, ALDH5A1, SDHB | ABL1 1045/4885SRC 3048/4885NUDT1 1609/4885 |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, ALK | ABL1 440/4885SRC 1538/4885NUDT1 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.